Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62  by Rodriguez, Angelina et al.
A R T I C L EMature-onset obesity and insulin resistance in mice deficient in
the signaling adapter p62
Angelina Rodriguez,1 Angeles Dura´n,1 Mohammed Selloum,4 Marie-France Champy,4 Francisco J. Diez-Guerra,1
Juana Marı´a Flores,2 Manuel Serrano,3 Johan Auwerx,4 Marı´a T. Diaz-Meco,1,5 and Jorge Moscat1,5,*
1 Centro de Biologı´a Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientı´ficas, Universidad Auto´noma de Madrid, Cantoblanco,
28049 Madrid, Spain
2 Departamento de Medicina y Cirugia Animal, Facultad de Veterinaria, Universidad Complutense, 28040 Madrid, Spain
3 Centro Nacional de Investigaciones Oncolo´gicas, Melchor Ferna´ndez Almagro 3, 28029 Madrid, Spain
4 Institut Clinique de la Souris, 67404 Illkirch, France
5 These authors contributed equally to this work.
*Correspondence: jmoscat@cbm.uam.es
Summary
Signalingcascades that control adipogenesis are essential in the regulationofbodyweight andobesity. Theadaptor p62con-
trols pathways thatmodulate cell differentiation.We report here that p622/2mice developmature-onset obesity, leptin resis-
tance, as well as impaired glucose and insulin intolerance. Themetabolic rate was significantly reduced in p622/2 nonobese
mice, which displayed increasedmRNA levels of PPAR-g and reduced levels of UCP-1 in adipose tissue. Basal activity of ERK
was enhanced in fat from nonobese mutant mice. Embryo fibroblasts from p622/2mice differentiated better than the wild-
type controls into adipocytes, whichwas abrogated by pharmacological inhibition of the ERKpathway. p62 is induced during
adipocyte differentiation and inhibits ERK activation by direct interaction. We propose that p62 normally antagonizes basal
ERK activity and adipocyte differentiation and that its loss leads to the hyperactivation of ERK that favors adipogenesis and
obesity.Introduction
The understanding of the signaling pathways that regulate
adipocyte growth and differentiation have been the matter of in-
tense research because they would provide new therapeutic op-
portunities for the treatment of obesity, a worldwide pathological
process leading to atherosclerosis and cardiovascular diseases
as well as type 2 diabetes (Flier, 2004). Recent molecular studies
are beginning to unravel the signal transduction cascades that
go awry during the onset of obesity and that presumably are
the causative agents of the disease. Leptin, insulin, and other
cytokines and growth factors acting peripherally or centrally
play relevant roles in the genesis of obesity and/or its complica-
tions (Flier, 2004). In addition, a number of signaling molecules
involved in the control of cell growth, differentiation, and apopto-
sis have been recently implicated in regulating adiposity and
obesity in several systems (Fajas et al., 2002; Hirosumi et al.,
2002; Kim et al., 2004; Matsumoto et al., 2003; Molero et al.,
2004; Nakae et al., 2003; Suzawa et al., 2003; Um et al., 2004).
We have recently identified p62 as a scaffold protein that serves
to locate the atypical PKCs (aPKC; PKCzand PKCl/i) in selective
signaling pathways (Sanchez et al., 1998), conferring specificity
to these kinases (Moscat and Diaz-Meco, 2000). In keeping with
its scaffold role, p62 consists of a series of modules that interact
with relevant signaling proteins. Thus, through its N-terminal AID
(OPCA)-containing PB1 region, p62 binds to the homologous
PB1 domain of the aPKC, whereas it binds TRAF6 through a rel-
atively small stretch of amino acids located in the central part of
the protein (Sanz et al., 2000). Studies demonstrated that TRAF6
is a critical regulator of osteoclastogenesis and bone remodeling
in vivo (Kobayashi et al., 2001; Lomaga et al., 1999). Interestingly,CELL METABOLISM 3, 211–222, MARCH 2006 ª2006 ELSEVIER INC.mutations in the p62 gene have been shown to cause the 5q35-
linked Paget’s disease of bone, a disorder characterized by
aberrant osteoclastic activity (Laurin et al., 2002). The recent
generation in our laboratory of the p62 knockout (KO) mice has
revealed that the loss of p62, which although it does not produce
major alterations in the basal physiology of bones, clearly pro-
duces defects in osteoclastogenesis when mice are challenged
with the calciotropic hormone PTHrP, and in vitro when bone
marrow osteoclast precursors were activated with RANK-L
(Duran et al., 2004). More recent results from this laboratory
demonstrate thatas thep622/2micemature theydisplayasignif-
icant increase in bone density (M.T.D.-M. and J.M., unpublished
data), consistent with the role of p62 in osteoclast differentiation.
We report here that as the p62 KO colony age, these mice be-
come obese and insulin resistant, strongly suggesting that the
loss of p62 leads to mature-onset obesity. The detailed biochem-
ical analysis of these mice reveals that the loss of p62 leads to
enhanced basal ERK activity that is essential for the control of
adipocyte differentiation. These results uncover a novel role for
p62 in the control of metabolic pathways leading to obesity
and insulin resistance.
Results
Mature-onset obesity in p622/2 mice
The understanding of the signaling pathways that regulate adi-
pocyte growth and differentiation is essential to identify new
therapeutic targets in obesity. The scaffold protein p62 consists
of a series of modules that interact with relevant signaling pro-
teins involved in cell growth and differentiation (Duran et al.,
2004). When p622/2 mice were compared with wild-type (wt)DOI 10.1016/j.cmet.2006.01.011 211
A R T I C L EFigure 1. Mature-onset obesity in p622/2 mice
A)Body weight of p622/2 (KO) and wt mice at different times, (B andC) photographs showing 10-month-old female wt and p62 ko mice; fat and lean mass of p622/2 and wt
mice measured by DXA of obese (D) and young male (2-month-old) mice (E and F); (H) food intake, and (G) water intake of wt and p622/2 mice at various ages; (I) oxygen
consumption of p622/2 and wt young male mice. Results are the mean 6 SD of 10 for each genotype.212 CELL METABOLISM : MARCH 2006
p62 and adipogenesiscontrols identically treated, no differences were observed in
body weight during the first 3 months of age. However, the
weight of p622/2 mice started to deviate at 4 months of age,
and differences become statistically significant at 5 months
and remained so until nearly 9 months when the last measure-
ment was performed (Figure 1A). At this time point, the p622/2
mice were visibly larger than the wt (Figure 1B), and upon surgi-
cal dissection it was apparent that the p622/2 mice have signif-
icantly increased body fat (Figure 1C). The increase in body fat in
mature p622/2 mice was also detected by dual X-ray absorpti-
ometry (DXA) (Figure 1D). In contrast, changes in fat-free mass
(lean) in p62-deficient mice were much less apparent as com-
pared with the wt controls (Figure 1D). Interestingly, increased
fat content was even found in young, nonovertly obese p62
mutant mice (Figure 1E), which show a statistically significant
increased percentage of fat and a concomitant reduction in the
percentage of lean mass (Figure 1F). Food intake was also signif-
icantly higher in the p622/2 mice (Figure 1H), but no differences
between wt and mutant mice were observed when the ratio of
food intake versus body weight was compared (data not shown).
When wt and p62-deficient mice were pair-fed, it became clear
that the weight of p622/2mice was higher than that of pair-fed wt
controls (Figure S1A in the Supplemental Data available with this
article online), although there were not differences in food intake
between both phenotypes (Figure S1B). In contrast, water intake
was dramatically higher in the p622/2 mice from 5–6 months of
age as compared to identically treated wt controls (Figure 1G),
suggesting diabetes and/or insulin resistance. Importantly, the
metabolic rate was significantly reduced in p622/2 nonobese
mice, as indicated by a significant decrease in oxygen consump-
tion as compared to that of wt control mice (Figure 1I). The
amount of retroperitoneal, interscapular (Figure 2A), and inguinal
(data not shown) fat was significantly higher in mature mutant
mice as compared to the wt controls, and adipocytes were
also larger in the fat from p622/2 mice (Figure 2B). Livers of
p622/2 mice were severely enlarged (Figure 2C) with greatly
increased fat deposits (Figure 2D), consistent with a fatty liver
phenotype. p622/2 liver weight was 3-fold higher than that of
wt. All this suggests that the loss of p62 leads to mature-onset
obesity. The size (Figure 2C) and cellularity (data not shown) of
spleen in p622/2 mice were also increased as compared to the
wt controls. The spleen from the p622/2mice was also weightier
(6-fold) than the wt, as were the heart (2.5-fold) and kidneys
(2-fold), but no differences were observed in p622/2 brains.
Collectively, these results indicate that in addition to obesity,
p622/2 mice also display overgrowth of at least some tissues
but when the percentage of fat versus lean is compared
(Figure 1F), it is clear that even in young mice the proportion of
fat is larger than in wt controls, whereas that of lean is reduced
in p622/2 mice (Figure 1F). Although both males and females
become similarly obese when mature (data not shown), how-
ever, the increased fat content in young mutant mice was only
observed in the male population (Figures 1E and 1F) but not in
the mutant females (data not shown). The reason for this gender
difference in young mice are unclear. Preliminary results indicate
no differences in locomotor activity when wt and p62-deficient
mice were compared (data not shown). Interestingly, obese
p622/2mice displayed increased fat TNFamRNA levels as com-
pared to wt controls (Figure S2), consistent with the notion that
obesity leads to the appearance of an inflammatory state (Arkan
et al., 2005; Cai et al., 2005).CELL METABOLISM : MARCH 2006Analysis of the messenger RNA levels of genes involved in en-
ergy combustion and adipocyte differentiation (Figure 3) reveals
significantly decreased levels of acyl-CoA oxidase in brown ad-
ipose tissue (BAT), and of carnitine palmitoyltransferase-1 in
BAT and muscle of the p622/2 mice, as well as decreases in
UCP-1 and UCP-2 in adipose tissue and of UCP-3 in muscle.
In addition, mRNA levels of PGC-1a and b were significantly
reduced in the liver of the p622/2mice. Glucose-6-phosphatase
mRNA levels were not changed by the loss of p62, whereas
those of phophoenolpyruvate carboxykinase were significantly
reduced in the liver of the p62 mutant mice. Leptin mRNA levels
were unchanged but, interestingly, PPAR-g mRNA levels were
increased in WAT from p62-deficient mice. Collectively, these
results suggest increased adipogenesis and lower energy
expenditure in p622/2 mice consistent with the data showing
increased fat content (Figures 1A–1H) and decreased oxygen
consumption (Figure 1I) in p622/2 mice. These results are even
more remarkable if it is taken into account that the tissue
samples were obtained from young (2-month-old) nonobese
p62-deficient and wt female mice, which at this stage do not
show yet changes in the content and percentage of fat, suggest-
ing that the alterations reported here are not secondary to the
obese phenotype but seem to be intrinsic to the loss of p62.
Histological analysis of the p622/2pancreas reveals severe is-
let hyperplasia with some cysts (Figure S3A). Immunostaining
analysis using anti-insulin antibody indicates increased number
of b-cells in p622/2 pancreas with no alterations in the number
of cells expressing glucagon, somatostatin, and pancreatic pep-
tide. Immunostaining with insulin and glucagon antibodies
shows a higher ratio of b-cell to a-cell in the p622/2 pancreas
(Figure S3A). Despite the hyperplastic islets, serum and glucose
basal levels were normal in fasting (Table 1) but were slightly in-
creased in fed p622/2mice (data not shown). Serum triglyceride
and cholesterol levels were dramatically increased, as were the
levels of leptin, consistent with the obese phenotype of the p622/2
mice. An important consequence of obesity is leptin and insulin
resistance. In keeping with this, leptin i.c.v. administration in
the hypothalamus demonstrates inhibited Stat3 phosphorylation
in obese p622/2 mice but not in young mutant mice in which
the obese phenotype was not apparent yet (Figure S3B). Glu-
cose and insulin tolerance tests demonstrate that the loss of
p62 impairs glucose and insulin tolerance (Figures S3C and
S3D). In addition, the induction of Srebpc1 in response to refeed-
ing was also inhibited in fat but not in liver of p622/2mice (Figures
S3E and S3F). These data indicate that the loss of p62 leads to
peripheral insulin resistance. Biochemical data are consistent
with this notion. Thus, whereas insulin robustly activates Akt in
wt tissues (Figure S4A), this parameter is severely abrogated in
p622/2 muscle and especially fat but not liver (Figure S4A). Sur-
prisingly, when S6K activity was determined in the above tissue
extracts, the loss of p62 did not impair insulin-activated S6K in
fat, liver, or muscle (Figure S4B). The degree of tyrosine phos-
phorylation of IRS-1 in response to insulin injection was severely
inhibited in fat (Figure S4C) and muscle (data not shown) of
p622/2 mice as compared to the wt controls. On the other
hand, when ERK activity was determined in fat extracts from
these mice, it was clear that ERK is potently activated by insulin
injection (Figure S4D). Importantly, basal ERK activity is dramat-
ically increased in p62-deficient fat to levels comparable to those
observed in insulin-injected mice (Figure S4D). This enhanced
basal ERK activity of p62 mutant mice was specific of the fat213
A R T I C L EFigure 2. Tissue morphology and histology of
p622/2 mice
Photographs of retroperitoneal (A, upper panel) and
interscapular (A, lower panel) fat pads and of liver
(C, upper panel) and spleen (C, lower panel) from
wt and p622/2 mice. Hematoxylin-eosin staining of
white adipose tissue (B) and liver (D, upper panel)
and Oil Red O staining (D, lower panel) of liver from
wt and p622/2mice. These are representative exper-
iments from another two with very similar results.tissue as no similar alterations were detected in muscle or liver
(data not shown). These results suggest that the loss of p62 leads
to increased basal ERK activity in fat.
Increased ERK activity in the fat of p622/2
nonobese mice
In order to determine whether these signaling defects were
directly related to the lack of p62 or were secondary to the obese
phenotype of the mutant mice, young nonobese wt and p62-
deficient mice were injected with insulin as above, after which
Akt and S6K activities were determined in muscle and fat. Re-
sults of Figures 4A–4C show that, in contrast to the data from
the p622/2 obese mice, Akt activation by insulin is not impaired
in muscle or fat of p62-deficient young nonobese mice. In addi-
tion, glucose and insulin tolerance tests performed in p622/2
nonobese mice revealed that the loss of p62 in young mice
does not lead to insulin resistance (Figure S5). This indicates
that the insulin resistance observed in the obese p622/2 mice
is secondary to obesity and is not an intrinsic defect of the
p62-deficient muscle or fat. As expected, S6K activation is not
affected in muscle or fat from p622/2 lean mice (Figures 4A
and 4C). Importantly however, ERK activity in fat of young non-
obese p62 mutant mice was clearly enhanced as compared to
the wt controls (Figure 4D), strongly suggesting that, in contrast
to the other parameters, increased ERK activity is an intrinsic214property of the p622/2 fat independently of the age or the obese
state of the mutant mice. The results of Figure 4E indicate that
this enhanced ERK activity is not due to increased levels or ac-
tivity of the insulin receptor in p62-deficient mice. Analysis of the
activity of MEK, the upstream regulator of ERK, demonstrates
that the loss of p62 does not result in higher but that it shows
even reduced phospho-MEK levels (Figure 4F), consistent with
the existence of a negative feed-back loop from the hyperacti-
vated ERK on MEK. These data strongly suggest that under
normal basal conditions p62 exerts a negative influence either
directly or indirectly on ERK but not on upstream steps of its
activation pathway.
Role of enhanced ERK activity in the increased
adipogenesis of p622/2 embryo fibroblasts
Since PPAR-gmRNA levels were increased in the WAT of p622/2
young mice (Figure 3), suggesting enhanced adipogenesis,
and ERK activity was also increased in the same tissue
(Figure 4D), and taking into account that ERK has been shown
to be important for adipogenesis and obesity (Bost et al.,
2005), we reasoned that the loss of p62 may be provoking in-
creased adipocyte differentiation through ERK what would
lead to obesity and insulin resistance. Therefore, we compared
the capacity of EFs from p622/2 mice with those of wt controls
to differentiate into adipocytes in vitro. The results of Figure 5ACELL METABOLISM : MARCH 2006
p62 and adipogenesisFigure 3. Effects of loss of p62 on mRNA levels of the indicated genes
Different tissues from wt and p622/2 mice were extracted and the mRNA levels of the different genes were determined by QRT-PCR. ACO, acyl-CoA oxidase; mCPT1,
muscle carnitine palmitoyltransferase-1; G6Pase, glucose-6-phosphatase; PEPCK, phophoenolpyruvate carboxykinase. BAT, brown adipose tissue; Li, liver; Mu, muscle;
WAT, white adipose tissue.show that wt EFs have a very limited but detectable ability to be-
come adipocytes in vitro giving a maximal response at 8 days
postinduction and declining thereafter. Interestingly, the EFs
from the p622/2mice gave rise to a robust adipogenic response
detectable at day 8 postinduction, which was further increased
at days 10–14. Therefore, the loss of p62 promotes adipogene-
sis, which may account for the obese phenotype of the p622/2
mice and the increased PPARg expression in WAT (see above)
and EFs (Figure S6) from these mutant mice. On the other
hand, the ectopic expression of p62 into the mutant EFs reduces
adipogenesis to wt levels (Figure 5B, left panel). Quantification of
lipid incorporation in these cultures further demonstrates the in-
creased adipogenesis observed in the KO EFs and that this is
due to the loss of p62. (Figure 5B, right panel). To determine
whether the increased ERK activation may be responsible for
that effect, the differentiation culture experiments were carried
out in the presence of the MEK inhibitor, PD98159. AccordingCELL METABOLISM : MARCH 2006to the data of Figure 5C, inhibition of ERK activation severely
abolishes the adipogenic response of p622/2EFs demonstrating
the important role of ERK in adipocyte differentiation. Data from
Figure 5D demonstrate the inhibition of ERK activation by the
MEK inhibitor in these cell cultures.
Table 1. Summary of plasma parameters after overnight fasting
Wild-type Knockout
Triglycerides (mg/dl) 102 6 24 202 6 53
Cholesterol (mg/dl) 84 6 18 149 6 22
Glucose (mg/dl) 93 6 44 100 6 16
Insulin (ng/ml) 0.5 6 0.2 0,7 6 0,2
Leptin (pg/ml) 1386 6 86 9382 6 819
Values are for 7-month wild-type (wt) and p622/2 (knockout, KO) mice. Data
represent mean 6 SD of five mice of each phenotype.215
A R T I C L EFigure 4. Insulin signaling defects in p622/2 mice
Young nonobese wt and p622/2mice were i.p.-injected with insulin, after which muscle extracts were analyzed for phospho-S6K and S6K (A), or phospho-Akt and Akt (B).
Fat extracts were analyzed for phospho-S6K and S6K, as well as phospho-Akt and Akt (C), phospho-ERK and ERK, and phospho-JNK (D), phosphotyrosine insulin re-
ceptor-b and insulin receptor-b levels (E), or phospho-MEK and MEK (F). These are representative experiments of another two with very similar results.p62 inhibits ERK function via a sequestration complex
In order to understand the mechanism whereby the loss of p62
leads to enhanced ERK activity, we first induced 3T3-L1 cells
to differentiate into adipocytes following a standard procedure,
and p62 expression was determined at different times thereafter.
In parallel, phospho-ERK and ERK levels were determined also
at different times during adipocyte differentiation. Of note, p62
protein levels were increased as soon as 30 min after the induc-
tion of the adipogenic differentiation program, peaked around
1–6 hr, and remained elevated at least for 12 hr. At 3 days after
induction, p62 declined to nearly basal levels (Figure 6A). Of
potential functional relevance, ERK was maximally activated at
1h followed by a reduction at 6 and 12 hr after induction, which
interestingly coincided with the maximal expression of p62
(Figure 6A). ERK activity was again significantly increased at 3
days of differentiation, at which time p62 levels were back to
basal levels (Figure 6A). These results demonstrate that p62 is in-
duced upon adipocyte differentiation and seems to antagonize
ERK activation, consistent with the observation in the KO mice
and cells. To directly address this possibility, we generated
3T3-L1 cell lines retrovirally transduced with either a control
vector or a vector expressing a HA-tagged version of p62. These
cells were induced to differentiate as above and phospho-ERK
levels were determined. Results from Figure 6B clearly demon-
strate that the ectopic expression of p62 ablates ERK activity216during adipocyte differentiation. Importantly, this effect results
in inhibition of C/EBPb (Figure 6C) and PPAR-g (Figure 6D) in
these cell cultures, consistent with the concept that p62 inhibits
adipogenesis by blocking ERK activity. To further support this
notion, we generated 3T3-L1 cells with p62 depleted levels by
retrovirally transducing shRNAmir for p62 or GFP, as a control.
Results of Figure 6E demonstrate the efficient depletion of p62
in the RNA interference cells. Afterwards, p62-depleted or con-
trol cells were induced to differentiate and the levels of phos-
pho-ERK were determined. Interestingly, and consistent with
our observations in fat from p622/2 mice, basal phospho-ERK
levels were significantly increased in the p62-depleted as com-
pared to the GFP control cells (Figure 6F). Of note, although early
activation of ERK is significantly enhanced in the p62-depleted
cells (Figure 6F, upper panel), the sustained stimulation of ERK
detected at days 3 and 6 following differentiation was not
specially increased in the p62-depleted cells (Figure 6F, lower
panel). Of note, adipocyte differentiation is significantly acceler-
ated in the p62-depleted 3T3-L1 cells (Figure 6G).
We reasoned that a mechanism whereby p62 could be im-
pacting ERK activity and function might involve the direct inter-
action of both proteins. To address this possibility, 293 cells
were transfected with a Myc-tagged p62 expression vector
along with a HA-tagged ERK construct, after which cells were
stimulated or not with insulin for 7 and 15 min, extracts wereCELL METABOLISM : MARCH 2006
p62 and adipogenesisFigure 5. ERK-dependent enhanced adipocyte differentiation of p622/2 EFs
EFs from wt and p622/2 (KO) mice were induced to differentiate into adipocytes and stained with Oil Red O (A). KO cells were retrovirally transduced with either a control or
a p62 expression vector after which they were induced to differentiate for 14 days and stained as above (B, left panel). Quantification of lipid incorporation by measuring the
intensity of Oil Red O in the same cultures (B, right panel). In other experiments (C) p622/2 cells were incubated with the selective MEK inhibitor PD98159 and the adipo-
genesis experiments were performed as above. (D) Immunoblot analysis of extracts demonstrates the inhibition of ERK activity by PD98059 treatment. These are repre-
sentative experiments from another two with very similar results.prepared and coprecipitation of ERK with p62 was determined.
Results of Figure 7A (left panel) show that p62 is in a complex
with ERK under basal conditions and that the interaction of
both proteins is enhanced upon the insulin challenge. Coimmu-
noprecipitation control experiments (Figure 7A, right panel),
demonstrate the specificity of these interactions. We next incu-CELL METABOLISM : MARCH 2006bated in vitro translated His-ERK with recombinant bacterially
expressed MBP-p62, after which MBP-p62 was recovered in
amylose beads, and the associated labeled His-ERK was deter-
mined. Interestingly, ERK was able to bind directly MBP-p62 but
not MBP alone (Figure 7B). When ERK activation is monitored in
extracts from 293 cells transfected or not with Myc-p62 along217
A R T I C L EFigure 6. Essential role of p62 in adipocyte differentiation and ERK activity in 3T3-L1 preadipocytes
(A) 3T3-L1 cells were induced to differentiate into adipocytes following a standard procedure, after which the levels of p62, phospho-ERK, and ERK were determined at
different times by immunoblotting. (B) 3T3-L1 cell lines retrovirally transduced with either a control vector or a vector expressing an HA-tagged version of p62 were induced
to differentiate as above and phospho-ERK, ERK, and HA-p62 levels were determined. Similar experiments were carried out to determine the levels of C/EBPb (C) by
immunoblotting or of PPAR-g mRNA by RT-PCR (D). Depletion of p62 in 3T3-L1 cells retrovirally transduced with shRNA vector for p62 interference (p62i) but not for
GFP (GFPi) (E). These cells were induced to differentiate as above and phospho-ERK and ERK levels were determined at different times (F). 3T3-L1 cells p62-depleted
by shRNA retroviral transduction as described above were induced to differentiate for 3 and 6 days and PPAR-g protein levels were determined by immunoblot analysis
(G). These are representative experiments of at least another two with similar results.with HA-ERK, it is clear that ERK activation, both endogenous
and ectopic, is dramatically inhibited by the expression of p62
(Figure 7C). Of note, Myc-p62 expression in 293 cells abrogates
the nuclear translocation of phospho-ERK following insulin acti-
vation (Figure 7D). Again, these results are in keeping with
a model according to which the sequestration of ERK by p62
serves to inhibit its enzymatic activity and function. In agreement
with this conclusion are the results of the immunofluorescence
experiments of Figure 7E. In those studies, 3T3-L1 cells were
transfected with Myc-p62 along with HA-ERK (upper panel),
after which they were stimulated with insulin and their colocaliza-
tion was determined by confocal microscopy. As shown in
Figure 7E (upper panel), there is a clear colocalization of p62
with ERK in p62 structures (Sanchez et al., 1998). This observa-
tion reinforces the notion that p62 serves to sequester ERK,218which leads to the inhibition of its enzymatic activity and func-
tion. Interestingly, p62 utilizes a characteristic lysine located in
its PB1 domain to interact with acidic residues situated in the
PB1s of kinases such as the atypical PKCs or MEK5 (Hirano
et al., 2004; Moscat and Diaz-Meco, 2002; Wilson et al., 2003).
ERK has an acidic docking site (Tanoue et al., 2000) that even
though is not part of a PB1 domain, resembles the negatively
charged amino acids of the PB1s of proteins involved in the inter-
action with the critical lysine of the PB1 of p62. To determine
the role that this lysine might play in the interaction of p62 with
ERK, this residue was mutated to alanine to generate the
HA-tagged mutant construct p62K7A, which was transfected
into 3T3-L1 cells. Of note, whereas wt p62 colocalizes with
ERK (Figure 7E, upper panel), the mutant protein does not
(Figure 7E, lower panel), strongly suggesting that p62 uses theCELL METABOLISM : MARCH 2006
p62 and adipogenesisFigure 7. Control of ERK by p62
293 cells transfected with a Myc-tagged p62 expression vector along with a HA-tagged ERK construct, were stimulated or not with insulin for 7 and 15 min, extracts were
prepared, and coprecipitation of ERK with p62 was determined by immunoblot analysis (A, left panel). As a specificity control, cells were transfected with Myc-p62 either
alone (2) or with HA-ERK (+), after which ERK was immunoprecipitated with anti-HA antibody, and the associated Myc-p62 was detected by immunoblotting (A, right panel).
In vitro translated His-ERK was incubated with MBP or increasing amounts of MBP-p62, and the ability of ERK to directly bind p62 was determined in pull-down experiments
with amylose beads (B). 293 cells transfected with a control vector or with a Myc-p62 expression plasmid along with HA-ERK were stimulated with insulin as above and
phospho-HA-ERK, HA-ERK, and endogenous phospho-ERK were determined by immunoblotting (C). 293 cells transfected with or without Myc-p62 were stimulated
with insulin for 5 min, after which nuclear extracts were prepared and phosphoERK levels determined by immunoblotting (D). 3T3-L1 cells were transfected with
Myc-p62 or Myc-p62K7A along with HA-ERK, after which they were stimulated with insulin and confocal colocalizations were determined (E). In a parallel experiment,
Myc-p62 was cotransfected with HA-MEK, and samples were processed as above (F). These are representative experiments of at least another two with similar results.basic face of its PB1 domain to sequester ERK. On the other
hand, Figure 7F demonstrates that in contrast to what is ob-
served with ERK, MEK does not colocalize with p62. On the other
hand, the fact that p62 sequesters ERK but is unable to bind
MEK suggests that it may preclude the access of MEK to ERK.
In this regard, preliminary data suggest that p62 blocks the abil-
ity of MEK to interact with ERK in vitro (data not shown).
Discussion
The results shown here are consistent with a model according
to which the loss of p62 results in enhanced ERK activity, in-CELL METABOLISM : MARCH 2006creased adipogenesis in vitro, and obesity in vivo. Consistently,
p62-deficient obese mice were insulin resistant as determined
by glucose intolerance tests, lower hypoglycemic response to
insulin, and a dramatic inhibition in the activation of Akt in re-
sponse to insulin in fat and muscle in vivo. The increased ERK
activity observed in the mutant fat is important for the enhanced
adipogenesis detected in p622/2 EFs, since treatment of these
cells with a MEK selective inhibitor during the differentiation pro-
cess completely abrogates adipogenesis, which is consistent
with the proposed role of ERK in adipogenesis in vitro and obe-
sity in vivo (Bost et al., 2005). The direct interaction of p62 with
ERK likely accounts for its role as a negative regulator of ERK219
A R T I C L Eactivity and function. Interestingly, our results show that al-
though the obese phenotype is observed in mature mutant
mice, the first signs of fat accumulation as determined by DXA
were already detected in young p622/2 male mice, which also
show a significant decrease in oxygen consumption as com-
pared with age-matched wt controls. Furthermore, we detected
also increased PPAR-g and decreased UCP-1, UCP-2, and
UCP-3 mRNA levels in young p622/2 mice, which do not yet
show signs of fat accumulation by DXA or decreased oxygen
consumption. Therefore, the most likely interpretation for our
data is that the loss of p62 leads to the activation of a gene pro-
gram that promotes enhanced adipogenesis and decreased en-
ergy expenditure even before the first signs of obesity are overtly
detectable. The observations reported here that the loss of p62
leads to enhanced basal ERK activity underlies the biochemical
mechanisms responsible for this phenotype, since ERK1-defi-
cient mice are lean, displaying the opposite phenotype to that
of p622/2 mice. The fact that not only PPAR-g levels are in-
creased in WAT of p62-deficient mice but that also UCP-1 levels
are decreased in BAT may suggest that a defect in energy ex-
penditure may also contribute to the phenotype of the p622/2
mice. This could be interpreted, as that p62 is not only involved
in WAT induction but also in BAT function. However, preliminary
cell culture experiments do not seem to support a role of p62 in
BAT cell differentiation at least in vitro (data not shown), although
further studies will be required to fully clarify this question.
It should be taken into account that a number of studies
reported that a finely tuned regulation of ERK activity is essential
for an adequate control of adipocyte differentiation in in vitro cell
culture model systems (Hu et al., 1996) (Kortum et al., 2005). On
the other hand, it has been shown genetically in mice that ERK is
necessary for adipogenesis and adiposity in vivo (Bost et al.,
2005). Therefore, ERK actions in this differentiation program
must be tightly and temporally controlled since under certain
conditions ERK activity may also impair this process through
the phosphorylation and consequent inactivation of PPAR-g
function, although ERK activity is required for adipogenesis.
However, the results of Kortum et al., (2005) demonstrate that
supraphysiological activations of ERK between 5 to 14-fold are
required for its inhibitory role during adipogenesis in the KSR1-
transfected cell in vitro model system. Here we show that p62
plays an essential role in the control of basal ERK activity
in vivo and that its inhibition in vitro either pharmacologically or
by ectopic expression of p62 severely impairs adipocyte differ-
entiation. In this regard, it should be noted that depletion of
p62 by shRNA only affects basal and early activation of ERK
but not its late stimulation, which is the one that presumably
plays the negative role in adipogenesis (Hu et al., 1996). The
reasons for this selective temporal effects of p62 in this param-
eter are not totally clear but may be related to the fact that at later
times p62 levels are not induced as compared to the amount of
p62 observed at early time point following differentiation. There-
fore, whereas p62 may play a critical role in the control of basal
and early-activated ERK, other p62-independent mechanisms
are involved in keeping ERK activity under control. In this regard,
it has been reported that later ERK activation is controlled in ma-
ture adipocytes by induction of the phosphatase MKP-1 (Sakaue
et al., 2004). Taken together, all these observations suggest that
an appropriate control of basal ERK activity is essential for the
maintenance of the homeostatic equilibrium in vivo that when
disrupted leads to obesity. Consistent with this notion, adipo-220cytes from obese patients with type 2 diabetes have higher
ERK basal activity than healthy controls (Carlson et al., 2003).
Intriguingly, high-fat diet stimulates ERK activity specifically in
WAT but not in liver or muscle (Bost et al., 2005). This suggests
the existence of cell-type specific functions for ERK and p62 as
only fat but not the other tested tissues display enhanced ERK
activity in the mutant mice.
It could be argued that the hyperactivation of ERK could also
account for the insulin resistance observed in p622/2mice since
it has been reported that IRS-1 phosphorylation during ERK
activation impairs IRS-1 tyrosine phosphorylation and function
(De Fea and Roth, 1997). However, in young mice in which
ERK activity in fat is increased, insulin-induced Akt activation
is not impaired. This suggests that enhanced ERK activity in
this system does not affect Akt activation and insulin function
but that its ability to promote adipogenesis and obesity is the
cause of insulin resistance in p62-deficient mice. Another impor-
tant observation of this study is that S6K activation by insulin is
not decreased in p62-deficient fat and muscle. In this regard,
recent results from Thomas and coworkers demonstrated that
S6K12/2 mice have a lean phenotype suggesting that S6K1
may be associated with obesity (Um et al., 2004). In fact, when
obesity is induced in mice fed with a high-fat diet, basal S6K1
activity is significantly increased as compared to mice fed with
normal diet (Um et al., 2004). In addition, the S6K12/2 mice
show hypersensitivity to insulin in vivo and in vitro and are resis-
tant to diet-induced obesity (Um et al., 2004). Interestingly,
S6K12/2 mice show enhanced oxygen consumption and in-
creased UCP1 mRNA levels, the opposite to the phenotype of
the p622/2 mice. Thus, our results, combined with those of
Thomas and coworkers, suggest that p62 and S6K display
antagonistic roles in the pathways that control adipogenesis
and obesity. It is possible that signals triggered by the obesity
produced by the loss of p62, indirectly makes S6K refractory
to the inhibitory pathways activated in the insulin-resistant state.
In this regard, S6K is regulated by mTor, which is inactivated by
the TSC1 and TSC2 tumor suppressors (Inoki et al., 2005; Man-
ning and Cantley, 2003; Nobukini and Thomas, 2004). Interest-
ingly, recent data suggest that ERK-induced phosphorylation
serves to inactivate TSC2 leading to S6K activation (Ma et al.,
2005). Therefore, it is possible that the loss of p62 that leads to
the hyperactivation of ERK may further feed in the S6K pathway
through TSC2-mTor, impeding its inhibition during insulin resis-
tance. More experiments should be required to fully clarify this
question.
In summary, we show here that the loss of p62 in vivo leads to
enhanced ERK activation and adipogenesis, which results in
obesity and insulin and leptin resistance. Alterations in energy
expenditure are also detected in p62-deficient mice. How this
contributes to the global obese phenotype of these mutant
mice, and its relation to the biochemical alterations in ERK
activity reported here, is unclear yet and will require further
investigation.
Experimental procedures
Reagents, antibodies, and plasmids
Reagents were purchased as follows: leptin was from Preprotech, insulin
was from Sigma, and PD98159 was from Calbiochem. Polyclonal anti-phos-
pho-Stat3, anti-phospho-AKT, anti-phospho-MEK, anti-AKT, anti-phospho-
S6K, and anti-JNK antibodies were from Cell Signaling. Anti-actin, anti-Stat3,
anti-phospho-ERK, anti-MEK, anti-phospho-JNK, anti-phospho-IRb, anti-ERK,CELL METABOLISM : MARCH 2006
p62 and adipogenesisanti-HA, anti-Myc, anti-C/EBPb, and anti-S6K antibodies were purchased
from Santa Cruz. Anti-insulin, anti-glucagon, and anti-somatostatin were
from Dako. Anti-IRbwas from Becton Dickinson and anti-PP was from Mono-
san. Anti-p62 polyclonal antibody was generated and affinity purified in our
laboratory. All antibodies were used according to manufacturers’ instruc-
tions. Expression plasmids for p62 (pcDNA3-Myc-p62; pcDNA3-HA-p62;
MBP-p62; pBabe-HA-p62), MEK (CMV-HA-MEK) and ERK (pcDNA1-HA-
ERK) have been previously described (Duran et al., 2004). The K7A p62 mu-
tant was generated by site-directed mutagenesis (QuickChange kit,
Stratagene). His-ERK was translated in vitro by the T7-TNT system (Prom-
ega). Retroviral shRNAmir in the pSM2c vector specific for mouse p62 were
purchased from Openbiosystems.
Mice
The p62 KO mice were described previously (Duran et al., 2004). All mice
were born and kept under pathogen-free conditions. Animal handling proto-
cols conform to the NIH guidelines. Sex-matched 10-month-old mice were
used for these studies. For the fasting-refeeding experiment, mice in the
fasted group were deprived of food for 24 hr; mice in the refed group were
deprived of food for 24 hr, and then allowed access to food for 12 hr before
analysis. For leptin i.c.v. injection, after mice were anesthetized, the skull was
exposed, and the bregma was located. The right lateral ventricle was injected
with 0.5 mg of leptin or buffer in a volume of 3 ml. Glucose-tolerance and
insulin-tolerance tests were performed on animals that had been fasted over-
night. Animals were injected with either 2 g/Kg body weight of glucose or 0.75
U/Kg body weight of human regular insulin into the peritoneal cavity. Glucose
levels were determined in blood collected from the tail tip immediately before
and 15, 30, 60, and 120 min after the injection using an Accuchek Advantage
glucometer (Roche Diagnostics). Insulin and leptin serum levels were mea-
sured by ELISA from Calbiochem and Linco Research, respectively. Choles-
terol and triglycerides plasma levels were determined by Labipath.
DXA analysis and energy expenditure measurements
DXA measurements in anesthetized mice were performed in an ultra high-
resolution densitometer PIXImus (GE Medical Systems) following standard
procedures. Energy expenditure was evaluated through indirect calorimetry
by measuring oxygen consumption with an Oxymax apparatus (Columbus
Instruments) over a 16 hr period including the dark phase (Picard et al.,
2002). Spontaneous locomotor activity was measured using individual
boxes, each composed with a sliding floor, a detachable cage, and equipped
with infra-red captors allowing measurement of ambulatory locomotor activ-
ity and rears. Boxes are linked to a computer using an electronic interface
(Imetronic, Pessac, France). Mice were tested for 32 hr in order to measure
habituation to the apparatus as well as nocturnal and diurnal activities. The
quantity of water consumed was measured during the test period using an
automated lickometer.
Histology and immunohistochemistry analysis
Adipose tissue, pancreas, and liver were fixed in 10% neutral buffer formalin
for 24 hr, dehydrated, and embedded in paraffin. Sections (5 mm) were cut
and stained with hematoxylin and eosin or prepared for immunohistochemis-
try by mounting tissue sections on electrostatically charged slides. Following
rehydration, quenching of endogenous peroxidase and blocking in normal
serum, tissues were incubated with anti-insulin, anti-glucagon, anti-somato-
statin, and anti-PP antibodies overnight at 4ºC, followed by incubation with
biotinylated secondary antibody. Antibodies were visualized with avidin-bio-
tin complex (Vectastain Elite, Vector Labs) using diaminobenzidine as a chro-
magen. Frozen liver sections were also stained with Oil Red O after fixation
with PFA.
Western blot
Adipose tissue was lysed by homogenization in modified RIPA buffer (50 mM
Tris-Hcl, [pH 7.4], 1% Triton X-100, 0.2% sodium deoxycholate, 0.2% so-
dium dodecylsulfate (SDS), 1 mM sodium ethylene diamine tetra acetate,
1 mM phenyl methyl sulfonyl fluoride, and protease inhibitors). Other tissues
or EFs were lysed in RIPA buffer (13 PBS, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 1 mM phenyl methyl sulfonyl fluoride, and prote-
ase inhibitors). Lysates were separated by SDS-PAGE and transferred to Ni-
trocellulose-ECL membranes (Amersham Biosciences) and the immune-
complex was detected by chemiluminescence (Amersham Biosciences).CELL METABOLISM : MARCH 2006For coimmunoprecipitation experiments, subconfluent 293 cells were trans-
fected with the different plasmids by the calcium phosphate method,
extracts were prepared in lysis buffer (25 mM Tris –HCl [pH 8], 100 mM
NaCl, 1% Triton-X100, 10% glycerol, and protease inhibitors), and immuno-
precipitations were carried out as previously described (Duran et al., 2004).
Gene expression analysis
Total RNA was extracted and DNase treated using Nucleospin RNA purifica-
tion kit from Becton Dickinson. The relative levels of Srebp1c, PPAR-g, and
TNF-a mRNAs were determined by real-time quantitative RT-PCR (LigthCy-
cler RNA Amplification Sybr Green, Roche) using actin mRNA for normaliza-
tion. Primer sequences used are as follows: for Srebp1c: 50-ATCGGCGCG
GAAGCTGTCGGGGTAGCGTC-30 and 50-ACTGTCTTGGTTGTTGATGAGC
TGGAGCAT-30; for PPAR-g: 50-GAACGTGAAGCCCATCGAGGAC-30 and
50-CTGGAGCACCTTGGCGAACA-30; and for TNF-a: 50-CATCTTCTCAAAA
TTCGAGTGACAA-30 and 50-TGGGAGTAGACAAGGTACAACCC-30.
Expression levels of genes involved in energy combustion and adipocyte
differentiation were analyzed in cDNA synthesized from total mRNA using
real-time PCR (Watanabe et al., 2004). The sequences of the primer sets
used are available at the following URL (http://www-igbmc.u-strasbg.fr/
recherche/Dep_GPSN/Eq_JAuwe/Publi/Paper.html).
Cell culture and adipocyte differentiation
EFs were isolated from 13.5 d.p.c. wt or p62 KO embryos and cultured in
DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, and 2 mM glutamine. 3T3-L1 were grown in DMEM containing either
10% calf serum (before differentiation) or 10% FBS (during differentiation).
Packaging of retrovirus and transduction were performed with pBabe and
pBabe-p62 retroviral vectors as described (Duran et al., 2004). 3T3-L1 cells
and p62 KO MEFs were transduced and selected with puromycin. For retro-
viral transduction of shRNAmir constructs, Linx cells were transfected with
Arrest-In transfection reagent (Openbiosystems) to generate virus-contain-
ing supernatants. For adipocyte differentiation studies, 3T3-L1 cell lines
and EFs were induced to differentiate 2 days after confluence (day 0) with
DMEM containing 10% FBS isobutylmethylxantine (0.5 mM), dexametha-
sone (1 mM), and insulin (10 mg/ml). In some experiments, cells were incu-
bated in the absence or in the presence of the selective MEK inhibitor
PD98159 (50 mM). For visualization of differentiated adipocytes, cells were
washed with PBS, fixed with PFA 4%, and stained in 0.5% Oil Red O in
dextrin, and then rinsed in distilled water for microscopic observation and
photography.
Confocal analysis
3T3-L1 and HeLa cells were transfected with Lipofectamine 2000 (Invitro-
gen). Insulin-treated cells were fixed with 4% formaldehyde and permeabi-
lized with 0.1% Triton X-100. Free aldehyde groups were quenched with
50 mM NH4Cl. Endogenous peroxidase activity was quenched by treatment
with 3% H2O2 in methanol for 15 min. Fixed cells were blocked in blocking
solution. Cells were incubated with the different antibodies (anti-HA and
anti-Myc) for 1 hr at 37ºC. The corresponding Alexa-488 or Allexa-594 sec-
ondary antibodies were used to directly detect the transfected proteins.
Glass cover slips were mounted on mowiol and examined with an MRC
1024 confocal system (Bio-Rad; Richmond, California) mounted on an Axio-
vert 135 microscope (Zeiss, Oberkochen, Germany).
Supplemental data
Supplemental data include six figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/3/3/211/DC1/.
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